Astrocyte elevated gene-1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/endothelin a receptor signaling

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 505-510

  Liu, Bo ^a   Wu, Yi ^a   Peng, Dan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Astrocyte elevated gene 1; Cell invasion; Chemoresistance; Endothelin; Endothelin 1; Osteosarcoma; Phosphatidylinositol 3 kinase; Receptor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; GELATINASE A; PUROMYCIN; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; ASTROCYTE ELEVATED GENE 1; CELL INVASION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NICK END LABELING; OSTEOSARCOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84871584591     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1056     Document Type: Article

References (17)

1. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13, 2010.
2. Gorlick R, Anderson P, Andrulis I, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9: 5442-5453, 2003.
3. Wittig JC, Bickels J, Priebat D, et al: Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician65: 1123-1132, 2002.
4. Su ZZ, Chen Y, Kang DC, Chao W, Simm M, Volsky DJ and Fisher PB: Customized rapid subtraction hybridization (RaSH) gene microarrays identify overlapping expression changes in human fetal astrocytes resulting from human immunodeficiency virus-1 infection or tumor necrosis factor-alpha treatment. Gene30: 67-78, 2003.
5. Liao WT, Guo L, Zhong Y, Wu YH, Li J and Song LB: Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma. J Transl Med 9: 205, 2011.
6. Lee SG, Su ZZ, Emdad L, Sarkar D and Fisher PB: Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A 103: 17390-17395, 2006.
7. Wang F, Ke ZF, Sun SJ, et al: Oncogenic roles of astrocyte elevated gene-1 (AEG-1) in osteosarcoma progression and prognosis. Cancer Biol Ther 12: 539-548, 2011.
8. Nelson J, Bagnato A, Battistini B and Nisen P: The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116, 2003.
9. Felx M, Guyot MC, Isler M, et al: Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-κB in human osteosarcoma. Clin Sci (Lond) 110: 645-654, 2006.
10. Zhao Y, Liao Q, Zhu Y and Long H: Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis. Clin Orthop Relat Res 469: 3190-3199, 2011.
11. Yoo BK, Chen D, Su ZZ, et al: Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res 70: 3249-3258, 2010.
12. Rosanò L, Cianfrocca R, Spinella F, et al: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelinA receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17: 2350-2360, 2011.
13. Ying Z, Li J and Li M: Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond. Cell Biosci 1: 36, 2011.
14. Yoo BK, Emdad L, Lee SG, et al: Astrocyte elevated gene-1 (AEG-1): a multifunctional regulator of normal and abnormal physiology. Pharmacol Ther 130: 1-8, 2011.
15. Zhang F, Yang Q, Meng F, Shi H, Li H, Liang Y and Han A: Astrocyte elevated gene-1 interacts with β-catenin and increases migration and invasion of colorectal carcinoma. Mol Carcinog: Mar 16, 2012 (Epub ahead of print). doi: 10.1002/mc.21894.
16. Sun P, Xiong H, Kim TH, Ren B and Zhang Z: Positive inter-regulation between β-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Mol Pharmacol 69: 520-531, 2006.
17. Rosenberg B, VanCamp L, Trosko JE, et al: Platinum compounds: a new class of potent antitumour agents. Nature 222: 385-386, 1969.